Aspirin halves colon cancer recurrence risk; new tumor testing recommended

A study indicates low-dose aspirin can halve colon cancer recurrence risk, prompting a new recommendation for all colon cancer patients to reanalyze tumors to identify eligible candidates. The finding is based on existing drug data, but the specific biomarker-driven benefit is newly emphasized. This could shift adjuvant therapy protocols and reduce recurrence rates, though implementation and validation details remain uncertain.